Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 10/20 | 0.56 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | PRKACG | P22612 | 1/20 | 0.38 |
| ▸ | PRKACB | P22694 | 1/20 | 0.38 |
| ▸ | VSIR | Q9H7M9 | 3/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291213 | 0.92 | CHEK1 (0.59) | CHEK1NR4A2ROCK2 | |
| SCHEMBL4294122 | 0.90 | CHEK1 (0.53) | CHEK1PRKACAPRKACGPRKACBVSIR | |
| SCHEMBL4294720 | 0.89 | CHEK1 (0.62) | CHEK1PRKACAPRKACGPRKACBNR4A2 | |
| SCHEMBL4297134 | 0.84 | CHEK1 (0.57) | CHEK1CDK8 | |
| SCHEMBL4300340 | 0.82 | CHEK1 (0.69) | CHEK1NR4A2CDK8 | |
| SCHEMBL4297838 | 0.82 | CHEK1 (0.56) | CHEK1NR4A2ROCK2 | |
| SCHEMBL4296990 | 0.81 | CHEK1 (0.65) | CHEK1NR4A2 | |
| SCHEMBL4291903 | 0.81 | CHEK1 (0.62) | CHEK1NR4A2CDK8 | |
| SCHEMBL4300984 | 0.81 | CHEK1 (0.64) | CHEK1NR4A2 | |
| SCHEMBL4291211 | 0.80 | CHEK1 (0.59) | CHEK1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | CHEK1, CHEK2, CDKN1A | CHEK1 1/4885PRKACA 652/4885PRKACG 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.